A phase II randomised, double-blind, stratified, multi-centre trial comparing the Nolvadex [tamoxifen] 20 mg and placebo combination to the Nolvadex 20 mg and ZD1839 [gefitinib] (IRESSA) 250 mg combination in patients with metastatic breast cancer and oestrogen receptor (ER) and/or progesterone (PR) positive tumors.

Trial Profile

A phase II randomised, double-blind, stratified, multi-centre trial comparing the Nolvadex [tamoxifen] 20 mg and placebo combination to the Nolvadex 20 mg and ZD1839 [gefitinib] (IRESSA) 250 mg combination in patients with metastatic breast cancer and oestrogen receptor (ER) and/or progesterone (PR) positive tumors.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2015

At a glance

  • Drugs Gefitinib (Primary) ; Tamoxifen
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Jul 2007 Status changed from in progress to completed.
    • 23 Nov 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top